The rapidly increasing prevalence of childhood obesity and its associated co-morbidities such as hypertriglyceridemia, hyper-insulinemia, hypertension, early atherosclerosis, metabolic syndrome, and non-alcoholic fatty liver disease are major public health concerns in many countries. Therefore the trends in child and adolescent obesity should be closely monitored over time, as in the near futur...

Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 agonist has recently been approved by FDA for type 2 diabetes in adults as single dose weekly. Tirzepatide is phase 3 development with obesity or overweight weight-related comorbidity. also under evaluation treatment of non-alcoholic steatohepatitis, heart faialure obstructive sleep apnea.

Background: Non-alcoholic fatty liver disease (NAFLD) has become over the last decade the most common form of chronic liver disease in children and adults. It is tightly associated with obesity and threatens to become a serious public health problem. Non-alcoholic steatohepatitis (NASH) is also commonly associated with type 2 diabetes mellitus (DM). Therefore, this study was carried out to know...